MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.970
+0.160
+8.84%
Pre Market 04:10 07/15 EDT
OPEN
1.850
PREV CLOSE
1.810
HIGH
1.990
LOW
1.810
VOLUME
409.65K
TURNOVER
--
52 WEEK HIGH
3.890
52 WEEK LOW
1.100
MARKET CAP
54.46M
P/E (TTM)
-1.3131
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GNCA stock price target is 16.00 with a high estimate of 32.00 and a low estimate of 5.00.

EPS

GNCA News

More
Genocea Biosciences Inc (GNCA): Are Hedge Funds Right About This Stock?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 07/06 13:27
Edited Transcript of GNCA.OQ earnings conference call or presentation 30-Apr-20 12:30pm GMT
Q1 2020 Genocea Biosciences Inc Earnings Call
Thomson Reuters StreetEvents · 06/23 19:52
Genocea Biosciences Highlights Will Present Data For ATLASTM-Identified Inhibigen Biology At AACR Meeting
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insights into the biology and
Benzinga · 06/22 13:01
Genocea to Present Data that Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology at AACR Virtual Annual Meeting II
Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insights into the biology and behavior of inhibitory neoantigens (Inhibigens™)  
GlobeNewswire · 06/22 13:00
Genocea Biosciences Granted Patent For ' VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE'
https://data.epo.org/publication-server/pdf-document?pn=2448592&ki=B1&cc=EP
Benzinga · 06/17 17:30
Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL Therapy
GlobeNewswire · 06/15 12:30
Genocea Biosciences Reports Investigational New Drug Application For GEN-011 For TIL Therapy
Benzinga · 06/15 11:36
Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A at Virtual ASCO 2020
GlobeNewswire · 05/29 13:00

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About GNCA

Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.
More

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.